Ironwood Pharmaceuticals, Inc.
NASDAQ:IRWD · NASDAQ Global Select
+$0.01 today
Vol 4.93M · Avg 2.35M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:IRWD · Revenue to Net Income
Key Ratios
Analysis
$361.5M of revenue converted into $102.2M of net income for the selected period. Gross margin is 99.7% and net margin is 23.5%, showing how much revenue survives after costs and taxes. EPS is $0.60, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $296.2M -15.7% | $351.4M -20.6% | $442.7M +7.8% | $410.6M -0.8% | $413.8M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 -100.0% | $7.6M +22.8% | $6.1M +333.6% | $1.4M -98.0% | $70.4M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $296.2M -13.9% | $343.9M -21.2% | $436.6M +6.7% | $409.2M +19.2% | $343.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 100.0% +2.1pp | 97.9% -0.8pp | 98.6% -1.0pp | 99.7% +16.7pp | 83.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $95.1M -14.6% | $111.4M -4.0% | $116.1M +162.3% | $44.3M -37.1% | $70.4M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $82.3M | $0 | $0 -100.0% | $116.0M | $0 | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $177.4M -29.3% | $250.7M -81.9% | $1.4B +770.1% | $158.8M +43.0% | $111.1M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.9M -6.5% | $2.0M +27.7% | $1.6M +11.1% | $1.4M -6.9% | $1.5M | $374.2M | $1.2B | $631.8M |
| EBITDA | $104.7M +7.1% | $97.7M -50.5% | $197.4M -24.5% | $261.4M +11.9% | $233.7M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 35.3% +7.5pp | 27.8% -16.8pp | 44.6% -19.1pp | 63.7% +7.2pp | 56.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | $118.8M +27.5% | $93.1M +109.8% | -$945.4M -477.7% | $250.3M +7.8% | $232.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 40.1% +13.6pp | 26.5% +240.0pp | -213.5% -274.5pp | 61.0% +4.8pp | 56.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $4.1M -8.8% | $4.5M -76.4% | $19.0M +99.7% | $9.5M +1208.7% | $726.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $32.7M -0.9% | $33.0M +52.7% | $21.6M +184.7% | $7.6M -75.6% | $31.1M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$48.7M -74.5% | -$27.9M -958.2% | -$2.6M -226.6% | $2.1M +106.6% | -$31.6M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $70.0M +7.4% | $65.2M +106.9% | -$948.1M -475.6% | $252.4M +25.8% | $200.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 23.6% +5.1pp | 18.6% +232.7pp | -214.1% -275.6pp | 61.5% +13.0pp | 48.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $46.0M -28.5% | $64.3M -23.0% | $83.5M +7.9% | $77.4M +123.6% | -$327.8M | $1.3B | -$1.6B | $745.2M |
| Net Income | $24.0M +2629.2% | $880.0K +100.1% | -$1.0B -672.5% | $175.1M -66.9% | $528.4M | $4.9B | $4.8B | $4.7B |
| Net Margin | 8.1% +7.9pp | 0.3% +226.6pp | -226.4% -269.0pp | 42.6% -85.1pp | 127.7% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $0 +2627.3% | $0 +100.1% | -$6 -670.8% | $1 -65.3% | $3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $0 +2627.3% | $0 +100.1% | -$6 -771.9% | $1 -70.1% | $3 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $162.2M +2.0% | $159.1M +2.3% | $155.4M +0.7% | $154.4M -4.9% | $162.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $177.8M +11.0% | $160.1M +3.0% | $155.4M -16.6% | $186.3M +13.3% | $164.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
BioAge Labs, Inc.
NASDAQ:BIOA
$775.07M
NeuroPace, Inc.
NASDAQ:NPCE
$518.91M
Canopy Growth Corporation
NASDAQ:CGC
$402.02M
Silence Therapeutics plc
NASDAQ:SLN
$324.73M
Cellectis S.A.
NASDAQ:CLLS
$316.31M
Alpha Teknova, Inc.
NASDAQ:TKNO
$275.58M
Lifecore Biomedical, Inc.
NASDAQ:LFCR
$208.55M
Aurora Cannabis Inc.
NASDAQ:ACB
$165.68M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$117.32M
Genelux Corporation
NASDAQ:GNLX
$108.90M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does IRWD generate?
Ironwood Pharmaceuticals, Inc. (IRWD) reported $296.15M of revenue in fiscal 2025.
Is IRWD profitable?
Ironwood Pharmaceuticals, Inc. (IRWD) reported $24.02M of net income, with a net margin of 8.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.